Dataset Information


Neoadjuvant combination PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable urothelial carcinoma

ABSTRACT: Immune checkpoint therapy (ICT) is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma (UC), with one study reporting data in cisplatin-ineligible patients who received anti PD-L1 monotherapy. The study reported that patients with bulky tumors, a known high-risk feature defined as greater than clinical T2 disease, had fewer responses, with pathologic complete response (pCR) rate of 17%. Here, we report on the first pilot combination neoadjuvant trial (NCT02812420) with anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab) in cisplatin-ineligible patients, with all tumors identified as having high risk features (N=28). Primary endpoint was safety and we observed 6 of 28 patients (21%) with grade ≥3 immune-related adverse events, consisting of asymptomatic laboratory abnormalities (N=4), hepatitis and colitis (N=2). We also observed pCR of 37.5% and downstaging to pT1 or less in 58% of patients who completed surgery (N=24). In summary, we provide initial safety, efficacy and biomarker data with neoadjuvant combination anti-PD-L1 plus anti-CTLA-4, which warrants further development for patients with localized UC, especially cisplatin-ineligible patients with high-risk features who do not currently have an established standard-of-care neoadjuvant treatment. Publication:

ORGANISM(S): Homo sapiens  

PROVIDER: EGAS00001004074 | EGA |


Similar Datasets

2019-01-01 | S-EPMC6815037 | BioStudies
2019-01-01 | S-EPMC6339669 | BioStudies
2016-01-01 | S-EPMC5730869 | BioStudies
2020-01-01 | S-EPMC7017288 | BioStudies
2020-01-01 | S-EPMC7336219 | BioStudies
2019-01-01 | S-EPMC6567914 | BioStudies
2019-01-01 | S-EPMC6935268 | BioStudies
2019-01-01 | S-EPMC6526676 | BioStudies
2018-01-01 | S-EPMC5878995 | BioStudies
2019-01-01 | S-EPMC6604807 | BioStudies